Biophysical Underpinnings of the Repeat Length Dependence of Polyglutamine Amyloid Formation

Levels of supramolecular chirality of polyglutamine aggregates revealed by vibrational circular dichroism

(2013) Dmitry Kurouski et al.   FEBS LETTERS

β-Hairpin-Mediated Nucleation of Polyglutamine Amyloid Formation

(2013) Karunakar Kar et al.   JOURNAL OF MOLECULAR BIOLOGY

Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynamics simulations

(2013) Miki Nakano et al.   JOURNAL OF MOLECULAR MODELING

Huntington's disease: underlying molecular mechanisms and emerging concepts

(2013) John Labbadia et al.   TRENDS IN BIOCHEMICAL SCIENCES

Polyglutamine neurodegeneration: expanded glutamines enhance native functions

(2012) Harry T Orr   CURRENT OPINION IN GENETICS & DEVELOPMENT

PolyQ disease: misfiring of a developmental cell death program?

(2012) Elyse S. Blum et al.   TRENDS IN CELL BIOLOGY

Cellular Inclusion Bodies of Mutant Huntingtin Exon 1 Obscure Small Fibrillar Aggregate Species

(2012) Steffen J. Sahl et al.   Scientific Reports

Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides

(2011) Andreas Vitalis et al.   BIOPHYSICAL CHEMISTRY

Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions

(2011) Aurélien Davranche et al.   HUMAN MOLECULAR GENETICS

Assays for studying nucleated aggregation of polyglutamine proteins

(2011) Murali Jayaraman et al.   METHODS

Amyloid-β forms fibrils by nucleated conformational conversion of oligomers

(2011) Jiyong Lee et al.   Nature Chemical Biology

Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent

(2011) Karunakar Kar et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An Antisense CAG Repeat Transcript at JPH3 Locus Mediates Expanded Polyglutamine Protein Toxicity in Huntington's Disease-like 2 Mice

(2011) Brian Wilburn et al.   NEURON

Autophagy and polyglutamine diseases

(2011) Maria Jimenez-Sanchez et al.   PROGRESS IN NEUROBIOLOGY

A Two-Step Path to Inclusion Formation of Huntingtin Peptides Revealed by Number and Brightness Analysis

(2010) Giulia Ossato et al.   BIOPHYSICAL JOURNAL

Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Mannerin Vitroandin Vivo

(2010) Justin Legleiter et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparative Characterization of Short Monomeric Polyglutamine Peptides by Replica Exchange Molecular Dynamics Simulation

(2010) Miki Nakano et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Huntington's disease: from molecular pathogenesis to clinical treatment

(2010) Christopher A Ross et al.   LANCET NEUROLOGY

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

(2010) Chiara Zuccato et al.   PHYSIOLOGICAL REVIEWS

Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?

(2010) T. Takahashi et al.   Journal of Molecular Cell Biology

Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease

(2009) Kirupa Sathasivam et al.   HUMAN MOLECULAR GENETICS

Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism

(2009) Ashwani K Thakur et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An Analytical Solution to the Kinetics of Breakable Filament Assembly

(2009) T. P. J. Knowles et al.   SCIENCE

A Comparison of Huntington Disease and Huntington Disease-Like 2 Neuropathology

(2008) Dobrila D. Rudnicki et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

CAG repeat lengths ≥335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse

(2008) I. Dragatsis et al.   NEUROBIOLOGY OF DISEASE